This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoshizumi, S.
Right arrow Articles by Yamaguchi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoshizumi, S.
Right arrow Articles by Yamaguchi, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 1998, p. 785-788, Vol. 42, No. 4
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

In Vivo Activity of HSR-903, a New Fluoroquinolone, against Respiratory Pathogens

Satoshi Yoshizumi,* Haruki Domon, Shuichi Miyazaki, and Keizo Yamaguchi

Department of Microbiology, Toho University School of Medicine, 5-21-16 Omori-Nishi, Ota-Ku, Tokyo 143, Japan

Received 19 May 1997/Returned for modification 6 August 1997/Accepted 11 January 1998

The in vivo activity of HSR-903, a new fluoroquinolone, against major bacteria which cause respiratory tract infections was evaluated. HSR-903 was active against experimental respiratory tract infections in mice challenged with penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae and Haemophilus influenzae strains. Treatment with HSR-903 reduced the bacterial numbers in infected murine lungs. In accord with the pulmonary clearance results, the rates of survival for mice treated with HSR-903, sparfloxacin, levofloxacin, ciprofloxacin, and benzylpenicillin were 50, 30, 10, 0, and 0%, respectively, 14 days after being infected with penicillin-resistant S. pneumoniae. A pharmacokinetic study with pneumonic mice showed that the levels of HSR-903 in the lungs were seven to eight times higher than those in the plasma. These results indicate that clinical studies of HSR-903 against respiratory tract infections may be warranted.

* Corresponding author. Present address: Department of Research, Hokuriku Seiyaku Co., Ltd., 37-1-1 Inokuchi, Katsuyama, Fukui 911-8555, Japan. Phone: 81 (779) 88-5121. Fax: 81 (779) 88-8021.

Antimicrobial Agents and Chemotherapy, April 1998, p. 785-788, Vol. 42, No. 4
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Higa, F., Arakaki, N., Tateyama, M., Koide, M., Shinzato, T., Kawakami, K., Saito, A. (2003). In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp.. J Antimicrob Chemother 52: 920-924 [Abstract] [Full Text]  
  • Okamoto, H., Miyazaki, S., Tateda, K., Ishii, Y., Yamaguchi, K. (2001). In Vivo Efficacy of Telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob. Agents Chemother. 45: 3250-3252 [Abstract] [Full Text]  
  • Yoshizumi, S., Takahashi, Y., Murata, M., Domon, H., Furuya, N., Ishii, Y., Matsumoto, T., Ohno, A., Tateda, K., Miyazaki, S., Yamaguchi, K. (2001). The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice. J Antimicrob Chemother 48: 137-140 [Abstract] [Full Text]  
  • Tomioka, H., Sato, K., Akaki, T., Kajitani, H., Kawahara, S., Sakatani, M. (1999). Comparative In Vitro Antimicrobial Activities of the Newly Synthesized Quinolone HSR-903, Sitafloxacin (DU-6859a), Gatifloxacin (AM-1155), and Levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium Complex. Antimicrob. Agents Chemother. 43: 3001-3004 [Abstract] [Full Text]  
  • Watanabe, A., Tokue, Y., Takahashi, H., Kikuchi, T., Kobayashi, T., Gomi, K., Fujimura, S., Nukiwa, T. (1999). In Vitro Activity of HSR-903, a New Oral Quinolone, against Bacteria Causing Respiratory Infections. Antimicrob. Agents Chemother. 43: 1767-1768 [Abstract] [Full Text]  
  • Murata, M., Tamai, I., Sai, Y., Nagata, O., Kato, H., Tsuji, A. (1999). Carrier-Mediated Lung Distribution of HSR-903, a New Quinolone Antibacterial Agent. J. Pharmacol. Exp. Ther. 289: 79-84 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»